首页> 外文期刊>Medical hypotheses >Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
【24h】

Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.

机译:晚期糖基化终产物可能参与糖尿病患者骨质疏松症的发病机制。

获取原文
获取原文并翻译 | 示例
           

摘要

Osteoporosis, one of the most prevalent metabolic bone diseases in developed countries, is a major public health problem through its association with fragility fractures. Several epidemiological studies have reported moderately increased risks of osteoporotic bone fractures in diabetic patients compared with general population. However, the underlying molecular link between diabetes and osteoporosis remains to be elucidated. In diabetes mellitus, the formation and accumulation of advanced glycation end products (AGEs) progress. There is a growing body of evidence to show that AGEs-their receptor (RAGE) interactions are involved in the development of atherosclerosis and diabetic microangiopathy. AGEs enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells. Furthermore, we have recently found that AGEs-RAGE interactions induced human mesenchymal stem cell apoptosis and subsequently prevented cognate differentiation into adipose tissue, cartilage, and bone. In vivo, serum levels of AGEs are elevated in patients with osteoporosis as well. These observations let us to hypothesize that AGEs could explain the molecular link between diabetes and osteoporosis. In this paper, we would like to propose the possible ways of testing our hypotheses. Does treatment with metformin, which has a potential effect on the inhibition of glycation reactions in vivo, decrease the risk for osteoporotic bone fractures in diabetic patients? If the answer is yes, is this beneficial effect of metformin superior to that of other anti-diabetic agents with equihypoglycemic properties? Does treatment with pyridoxamine, a post-Amadori inhibitor (so-called Amadorins) of AGE formation, reduce the risk for osteoporotic bone fractures as well? Furthermore, are increased levels of AGEs and RAGE in bone tissues associated with high risk for bone fractures in patients with diabetes? These clinical studies could clarify whether the AGEs-RAGE interactions serve as a causal link between diabetes and osteoporosis.
机译:骨质疏松症是发达国家中最普遍的代谢性骨病之一,它与脆性骨折有关,是主要的公共卫生问题。几项流行病学研究表明,与普通人群相比,糖尿病患者发生骨质疏松性骨折的风险有所增加。但是,糖尿病和骨质疏松症之间的潜在分子联系仍有待阐明。在糖尿病中,晚期糖基化终末产物(AGEs)的形成和积累不断发展。越来越多的证据表明AGEs及其受体(RAGE)的相互作用与动脉粥样硬化和糖尿病性微血管病的发展有关。 AGEs增强破骨细胞诱导的小鼠未分离骨细胞的骨吸收。此外,我们最近发现AGEs-RAGE相互作用诱导人间充质干细胞凋亡,并随后阻止同源分化为脂肪组织,软骨和骨骼。在体内,骨质疏松症患者的血清AGEs水平也升高。这些观察结果使我们假设AGEs可以解释糖尿病和骨质疏松症之间的分子联系。在本文中,我们想提出检验假设的可能方法。用二甲双胍治疗对体内糖化反应的抑制具有潜在作用,是否能降低糖尿病患者发生骨质疏松性骨折的风险?如果答案是肯定的,那么二甲双胍的这种有益作用是否优于其他具有降糖功能的抗糖尿病药?使用吡mad胺(一种Amadori后的AGE抑制剂)(所谓的Amadorins)治疗是否也降低了骨质疏松性骨折的风险?此外,糖尿病患者骨组织中AGEs和RAGE水平升高是否与骨折风险高相关?这些临床研究可以阐明AGEs-RAGE相互作用是否是糖尿病和骨质疏松症之间的因果关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号